Email this article Expression of the apoptosis-releated genes in patients with newly diagnosed chronic lymphocytic leukemia in clinical data context
- Authors: Zakharov S.G.1, Golenkov A.K.1, Misyurin A.V.2, Kataeva E.V.1, Rudakova A.A.2, Baryshnikova M.A.2, Mitina T.A.1, Trifonova E.V.1, Vysotskaya L.L.1, Chernykh Y.B.1, Klinushkina E.F.1, Belousov K.A.1, Finashutina Y.P.2, Misyurin V.A.2
-
Affiliations:
- MONIKI
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 17, No 2 (2018)
- Pages: 41-46
- Section: ORIGINAL REPORTS
- Published: 24.11.2018
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1086
- DOI: https://doi.org/10.17650/1726-9784-2018-17-2-41-46
- ID: 1086
Cite item
Full Text
Abstract
Introduction. The given data of fundamental studies of apoptosis processes in B-cell lymphocytic leukemia (B-CLL) testifies about the complexity and variety of mechanisms affecting the kinetics of normal cells and tumor lymphocytes in this disease. It is important to study the severity of clinical manifestations of the disease depending on the expression of the genes that modulate apoptosis.
The purpose of the study is to compare the activity of genes encoding apoptosis modulators, the cell cycle and cancer-testicular PRAME protein with clinical manifestations of the disease in primary patients with B-CLL.
Materials and methods. The level of expression of the proapoptotic genes FAS, TRAIL, TNFR2, DR4/5 and DR3, as well as the HSP27, XIAP genes, blocking apoptosis was determined in 23 patients with newly diagnosed chronic B-CLL. In addition, expression of genes TP53 and P21 and cancer-testis gene PRAME are tested.
Results. According to the multivariate regression analysis, the FAS gene expression in the onset of the disease had the greatest impact on the clinical characteristics of the disease. In this connection, the patients were divided into groups with normal (group) and low gene level (group II). A low level of FAS expression (Me 387 %) was associated with stage II disease (p = 0.03), a large number of lympho cytes (p = 0.001), fewer erythrocytes (p = 0.08), and a lower level of TNFR2 gene expression (p = 0.08), high level of expression of XIAP, HSP27, P21. Overall, the anti-apoptotic potential in Group II patients was higher, which was accompanied by more pronounced clinical manifestations of the disease.
Conclusions. The increased anti-apoptotic potential of tumor lymphocytes in newly diagnosed B-CLL is accompanied by a larger tumor mass and greater clinical and hematological manifestation of the disease.
About the authors
S. G. Zakharov
MONIKI
Author for correspondence.
Email: hematologymoniki@mail.ru
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationA. K. Golenkov
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationA. V. Misyurin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478
Russian FederationE. V. Kataeva
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationA. A. Rudakova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478
Russian FederationM. A. Baryshnikova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478
Russian FederationT. A. Mitina
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationE. V. Trifonova
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationL. L. Vysotskaya
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationYu. B. Chernykh
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationE. F. Klinushkina
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationK. A. Belousov
MONIKI
bldg. 1, 61/2 Shchepkina St., Moscow 129110
Russian FederationYu. P. Finashutina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478
Russian FederationV. A. Misyurin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
24 Kashirskoe Shosse, Moscow 115478
References
- Baryshnikov A.Yu. Principles and practice of vaccinotherapy for cancer. Byulleten Sibirskogo otdeleniya Rossiyskoy akademii medicinskih nauk = Bulletin of the Siberian Division of Russian Medical Sciences Academy 2004;24(2):59–63. (In Russ.)
- Baryshnikov A.Yu., Shishkin Yu.V. FAS/APO-1 antigen – apoptose condensing molecula. Gematologiya i transfuziologiya = Hematology and Transfusiology 1995;6:35–8 (In Russ.)
- Kitada S., Andersen J., Akar S. et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91(9):3379–89.
- Jablonska E., Kiersnowska-Rogowska B., Rogowski F. et al. TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Neoplasma 2008;55(1):51–4. doi: 10.1080/10428190500158789.
- Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nature Rev. Immunol. 2003; 3(9):745–56. doi: 10.1038/nri1184.
- Chakrabandhu K., Huault S., Garmy N. The extracellular glycosphingolipid-binding motif of Fas defines its internalization route, mode and outcome of signals upon activation by ligand. Cell Death Differ. 2008;15(12):1824–37. doi: 10.1038/cdd.2008.115.
- Ea C.K., Deng L., Xia Z.P. et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell. 2006;22(2):245–57. doi: 10.1016/j.molcel.2006.03.026.
- Falschlehner C., Ganten T.M., Koschny R. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv. Exp. Med. Biol. 2009;647:195–206. doi: 10.1007/978-0-387-89520-8_14.
- LeBlanc H.N., Ashkenazi A. Apo2L/ TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66–75. doi: 10.1038/sj.cdd.4401187.
- Meylan F., Richard A.C., Siegel R.M. TL1A and DR3, a TNF family ligandreceptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev. 2011;244(1):188–96. doi: 10.1111/j.1600-065X.2011.01068.x.
- Wen L., Zhuang L., Luo X., Wei P. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J. Biol. Chem. 2003;278(40):39251–8. doi: 10.1074/jbc.M305833200.
- Halina A., Artur P., Barbara M.K. et al. Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Folia Histochem Cytobiol. 2010;48(4):534–41. doi: 10.2478/v10042-010-0048-5.
- Sarto C., Binz P.A., Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000;21(6):1218–26. doi: 10.1002/(SICI)15222683(20000401)21:6<1218:AID- ELPS1218>3.0.CO;2-H.
- Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13(3):239–52.
- Paydas S., Tanriverdi K., Yavuz S., Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res. 2007;31(3):365–9. doi: 10.1016/j.leukres.2006.06.022.
- Gunn S.R, Bolla A.R, Barron L.L. et al. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res. 2009;33(9):1276–81. doi: 10.1016/j.leukres.2008.10.010.
- Hallek M., Cheson B.D., Catovsky D. et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood 2008;111(12):5446–56. doi: 10.1182/blood-2007-06-093906.
- Chomczynski P., Sacchi N. The singlestep method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: Twenty something years on. Nat Protoc. 2006;1(2):581–5. doi: 10.1038/nprot.2006.83.
Supplementary files
